Background IL-17F is produced by many cell types such as memory CD4+ T cells, CD8+ T cells, γδ T cells, NKT cells and B cells etc. IL-17F can induce various asthma-related cytokines, chemokines, and adhesion molecules in bronchial epithelial cells, eosinophils, fibroblasts, airway smooth muscle cells, and vein endothelial cells, and thereby contributes to the pathogenesis of asthma.
Objective In our study we tried to find out association of serum levels of IL-17 and total duration of illness in patients of Bronchial Asthma.
Materials and Methods We evaluated prospectively 66 cases of bronchial asthma and 20 controls from normal population with the help of proper history and relevant investigations [to rule out other diseases like COPD, ILD etc.] All Subjects were evaluated for serum IL-17 levels, by using ELISA kit of KOMA Biotech Inc. Obtained data was evaluated statically by using SPSS software.
Results We found Serum IL-17 levels significantly raised in Asthma patients as compared to control with t-value 7.066 and p-value <0.001.
Conclusion Asthma patients tend to have higher serum IL-17 levels than controls from normal population. So it can be a potential target for developing new drugs specially for steroid resistant bronchial asthma.
